Role of T-Cell Costimulation and Regulatory Cells in Allogeneic Hematopoietic Cell Transplantation

Blazar, Bruce R.; Taylor, Patricia A.

doi:10.1201/b14165-5

Cited by 2 publications

(2 citation statements)

References 272 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ICOS interaction is responsible for T-cell expansion and the effector phase of the immune response, in a CD28-independent fashion. Although the effect of blocking ICOS interaction was shown preferentially in chronic GHVD models, consistent with its effects on Th2 differentiation [ 37 ], studies done in fully allograft GVHD models have revealed a prominent role in the development of acute GVHD [ 23 ]. Thus, administration of an anti-ICOS antibody at the time of the SCT was very effective in reducing GVHD and improving survival in an acute GVHD model.…”

Section: Icos/icos-l Pathwaymentioning

confidence: 99%

See 1 more Smart Citation

T-Cell Costimulatory Molecules in Acute-Graft-Versus Host Disease: Therapeutic Implications

Briones

Novelli

Sierra

2011

Bone Marrow Research

View full text Add to dashboard Cite

Acute Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Although this process is thought to consist of several phases, T-cell activation plays a critical role in the pathogenesis of acute GVHD. To become efficient effectors, T-cells require additional costimulation after T-cell receptor signaling. A number of molecules are involved in costimulation of T-cells such as CD28, CD40L, CD30, OX40, 4-1BB, ICOS, and LIGHT. The system is regulated by inhibitory molecules, CTLA-4, and PD-1. There is experimental evidence that those molecules are implicated in the pathogenesis of GHVD. We describe how these molecules are involved in acute GVHD and how the blockade of costimulatory molecules may have potential implications for the treatment of patients with acute GVHD.

show abstract

Section: Icos/icos-l Pathwaymentioning

confidence: 99%

“…Studies comparing the blockade of CD40L versus CD28 pathway have shown that the use of anti-CD40L was significantly more effective than anti-B-7 antibodies in reducing GVHD [ 23 ]. In addition, experimental studies suggest that dual blockade of CD40L and CD28 pathway may be useful in reducing GVHD lethality.…”

Section: Cd40/cd40l Pathwaymentioning

confidence: 99%